CNS Pharmaceuticals, Inc.
CNSP
$4.59
-$0.30-6.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.55M | 6.21M | 5.10M | 5.42M | 5.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.62M | 15.99M | 13.20M | 15.58M | 15.69M |
| Operating Income | -16.62M | -15.99M | -13.20M | -15.58M | -15.69M |
| Income Before Tax | -16.49M | -15.85M | -13.07M | -15.46M | -15.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.49 | -15.85 | -13.07 | -15.46 | -15.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.49M | -15.85M | -13.07M | -15.46M | -15.61M |
| EBIT | -16.62M | -15.99M | -13.20M | -15.58M | -15.69M |
| EBITDA | -16.62M | -15.98M | -13.20M | -15.57M | -15.69M |
| EPS Basic | -29.18 | -40.81 | -66.59 | -214.03 | -207.61 |
| Normalized Basic EPS | -18.24 | -25.51 | -41.62 | -133.77 | -129.76 |
| EPS Diluted | -29.18 | -40.81 | -66.59 | -214.03 | -207.61 |
| Normalized Diluted EPS | -18.24 | -25.51 | -41.62 | -133.77 | -129.76 |
| Average Basic Shares Outstanding | 2.22M | 1.77M | 1.25M | 723.40K | 353.30K |
| Average Diluted Shares Outstanding | 2.22M | 1.77M | 1.25M | 723.40K | 353.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |